AltruBio Reports Phase 2a Data for Ulcerative Colitis
The investigational drug ALTB-268 showed promising clinical remission rates in a recent study of ulcerative colitis patients.
Updated on Oct. 20, 2026 in Biotech
Live Poll
Do you believe experimental drug treatments are worth the potential risks for patients with chronic conditions?
AltruBio has released results from its Phase 2a clinical trial for ALTB-268, an investigational treatment for therapy-refractory ulcerative colitis. Participants showed varying rates of clinical remission across two different dosing cohorts.
Why it matters
This trial addresses the significant unmet medical needs of patients who have previously failed to find relief through existing advanced therapies for ulcerative colitis. The findings offer a potential new therapeutic pathway for those managing the condition.
A cohort with target drug concentration levels achieved a 38.9% clinical remission rate after a 12-week induction period. Only one serious adverse event was reported throughout the study, with no deaths occurring.
The players
AltruBio
AltruBio is a San Francisco-based biotechnology company focused on developing novel therapeutics for inflammatory and immunological diseases.
The details
The study assessed the subcutaneous administration of ALTB-268 in patients with ulcerative colitis who had previously failed other therapies. Researchers utilized two sequential cohorts to test the drug at different dosage levels over the 12-week induction phase.
Timeline
Day 29: Trough concentration levels were measured in study participants.
Week 12: Clinical remission and patient response were formally assessed.
October 20, 2026: Phase 2a data was presented at UEG Week 2026.
2027: A global Phase 2b trial is expected to commence.
The Big Picture
This study follows the ongoing evolution of the development of advanced therapies for ulcerative colitis as manufacturers seek alternatives for therapy-refractory patients. It marks a potential expansion of available treatment options within that landscape.
While the drug is not yet available for prescription, the successful completion of this induction period suggests that future treatment options may soon expand for those who have not responded to current therapies. Patients should consult their gastroenterologists about ongoing clinical trials for their specific conditions.
The takeaway
The study demonstrates that ALTB-268 is well tolerated and shows clinical promise for hard-to-treat cases of ulcerative colitis. Researchers hope these initial results will provide a strong foundation for the upcoming, larger Phase 2b study.
What happens next
AltruBio is scheduled to launch a global Phase 2b clinical trial in 2027 that will evaluate the drug in both therapy-experienced and therapy-naïve patients.
Further reading
For more on the current landscape of experimental treatments, visit the Biotech section.
Live Poll
Do you believe experimental drug treatments are worth the potential risks for patients with chronic conditions?
